羧基麦芽糖铁:铁缺乏症治疗综述
本文综述静脉羧基麦芽糖铁在铁缺乏(±贫血)患者中的临床应用并简述其药理特性。基于临床试验和真实世界广泛经验,该药可快速补充铁储备并纠正贫血,总体耐受良好,且单次高剂量输注可能节省医保费用。
要点
- 羧基麦芽糖铁可单次高剂量15分钟输注,快速补充铁储备。
- 适用于口服铁剂无效或不能使用的铁缺乏成人及≥14岁儿童。
- 在慢性心衰、慢性肾病、炎症性肠病等患者中有效且耐受良好。
核心结论
- 羧基麦芽糖铁是成人及获批地区≥14岁儿童铁缺乏的重要治疗选择,适用于口服铁剂无效或无法使用的情况。
研究设计与样本
- 本文为综述,基于临床试验和真实世界广泛经验,总结羧基麦芽糖铁在铁缺乏(±贫血)患者中的临床应用并简述药理特性。
主要发现
- 羧基麦芽糖铁可快速补充铁储备并纠正贫血,总体耐受良好。
- 在慢性心衰、慢性肾病、炎症性肠病、围手术期贫血患者以及妊娠、产后或月经过多相关铁缺乏女性中有效。
- 单次高剂量输注可能从医保支付方角度节省费用。
临床怎么用
- 对于口服铁剂无效或不能使用的铁缺乏(±贫血)成人及获批地区≥14岁儿童,可考虑静脉羧基麦芽糖铁单次高剂量15分钟输注。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Intravenous ferric carboxymaltose (Ferinject®; Injectafer®) is a colloidal solution of nanoparticles which consist of a polynuclear iron (III)-(oxyhydr)oxide core stabilized by carboxymaltose and may be given as a single high-dose, 15-min infusion. This article reviews the clinical use of ferric carboxymaltose in various patient populations with iron deficiency (ID) [± anaemia] and briefly summarizes its pharmacological properties. Based on extensive experience in the clinical trial and real-world settings, ferric carboxymaltose is an effective and generally well tolerated treatment for rapidly replenishing iron stores and correcting anaemia in patients with ID (± anaemia) of various aetiologies, including patients with chronic heart failure (CHF), chronic kidney disease, inflammatory bowel disease or perioperative anaemia, and women with ID during pregnancy, postpartum or associated with heavy uterine bleeding. As it may be given as a single high-dose infusion, ferric carboxymaltose has the potential to provide cost savings from a healthpayer perspective. Thus, ferric carboxymaltose remains an important option for the treatment of ID in adults and, where approved, children aged ≥ 14 years, when oral iron preparations are ineffective or cannot be used.
引用
- Scott LJ. Ferric Carboxymaltose: A Review in Iron Deficiency. Drugs. 2018. PMID: 29532438. doi:10.1007/s40265-018-0885-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。